Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: Six-year prospective study using carotid ultrasonography

Hypertension Research

Volumn 31, Issue 6, 2008, Pages 1185-1189

  Furuki, Kumiko ^a   Adachi, Hisashi ^a   Enomoto, Mika ^a   Otsuka, Maki ^a   Fukami, Ako ^a   Kumagae, Shun Ichi ^a   Matsuoka, Hidehiro ^a   Nanjo, Yasuki ^a   Kakuma, Tatsuyuki ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Nitric oxide; Prospective study

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; INSULIN; N(G),N(G) DIMETHYLARGININE; ORAL ANTIDIABETIC AGENT; PURINE DERIVATIVE; URIC ACID LOWERING AGENT;

ADULT; AMINO ACID BLOOD LEVEL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BLOOD CHEMISTRY; CAROTID ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; ECHOGRAPHY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING;

AGED; ARGININE; ATHEROSCLEROSIS; CAROTID ARTERIES; DISEASE PROGRESSION; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUNICA INTIMA; TUNICA MEDIA;

EID: 48349085576     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1185     Document Type: Article

References (27)

1. Nakashima A, Matsuoka H, Yasukawa H, et al: Renal denervation prevents intraglomerular platelet aggregation and glomerular injury induced by chrosic inhibition of nitric oxide synthesis. Nephron 1996; 73: 34-40.
2. Ikeda H, Takjo Y, Murohara T, et al: Platelet-derived nitric oxide no coronary risk factors. Hypertension 2000; 35: 904-907.
3. Katoh A, Ikeda H, Takajo, Y, et al: Conscistence of impairment of endothelium-derives nitric oxide and platelet-derived nitric oxi de in patients with coronary risk factors. Circ J 2002; 66: 837-840.
4. Cooke JP, Dzpu VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
5. Ware JA, Heistad DD: Platelet-endothelium interactions. N Engl J Med 1993; 328: 628-635.
6. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
7. Matsuoka H, Itoh S, Kimoto M, et al: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242-247.
8. Miyazaki H, Matsuoka H, Cooke JP, et al: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.
9. Cooke JP: Does ADM cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-2037.
10. Achan V, Broadhead M, Malaki M, et al: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-1459.
11. Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D: Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003; 107: 1891-1895.
12. Surdacki A, Nowicki M, Sandmann J, et al: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Caradiovasc 1999; 33: 652-658.
13. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
14. Lundman P, Eriksson MJ, Stublinger M, Cooke JP, Hamsten A, Tornvall P: Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111-116.
15. Zoccali C, Bode-Boger SM, Mallamaci F, et al: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
16. Valkonen VP, Pälvä H, Salonen JT, et al: Risk of acute coronary events and serum concentration of asymmetrical dimethylargine. Risk of acute coronary events and serum concentration of asymmetrical dimethylargine. Lancet 2001; 358: 2127-2128.
17. Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH, Kähler J: Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005; 26: 1846-1851.
18. Furuki K, Adachi H, Matsuoka H, et al: Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery - an epidemiological study -. Atherosclerosis 2007; 191: 206-210.
19. Nanayakkara PW, Teerlink T, Stehouweer CD, et al: Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005; 68: 2230-2236.
20. Hino A, Adachi H, Toyomasu K, et al: Very long chain N-3 fatty acids intake and carotid atherosclerosis - an epidemiological study evaluated by ultrasonography -. Atherosclerosis 2004; 176: 145-149.
21. SAS Institute: SAS/STAT Software: Changes and Enhancements through Release 6.12. Cary, SAS Institute Inc, 1997.
22. O'Leary DH, Polak JF, Kbonmal RA, Manolio TA, Burke GL, Wolfson SK, for the Cardiovascular Health Study Collaborative Research Group: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.
23. Zoccali C, Benedetto FA, Maas R, et al: Asymmetric dimethylarginine, C-reactive protein, and carotid intimamedia thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-496.
24. Boger RH, Zoccali C: ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atherosclerosis 2003; 4: 23-28.
25. Zoccali C: Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006; 24: 611-619.
26. Pitt B, Byington RP, Furberg CD, et al: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-1510.
27. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001; 357: 577-581.